Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURMOUNT-OSA ISA1 (GPI1) tirzepatide in obstructive sleep apnea with obesity, unable/unwilling to use PAP
jRCT2031220154Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Randomised, double-blind trial in obstructive sleep apnea hypopnea syndrome (OSAHS) and obesity comparing Tirzepatide maximum tolerated dose with Placebo (2 arms). Primary endpoint: Percent change from baseline in apnea-hypopnea index (AHI). Started Oct 2022; status: completed.
02
Drugs
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)obesity
Beyond the preview
Go deeper on jRCT2031220154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220154.